[go: up one dir, main page]

BR9903571A - Método para inibição de glicogênio fosforilase humano - Google Patents

Método para inibição de glicogênio fosforilase humano

Info

Publication number
BR9903571A
BR9903571A BR9903571-5A BR9903571A BR9903571A BR 9903571 A BR9903571 A BR 9903571A BR 9903571 A BR9903571 A BR 9903571A BR 9903571 A BR9903571 A BR 9903571A
Authority
BR
Brazil
Prior art keywords
glycogen phosphorylase
inhibiting human
human glycogen
binding site
new
Prior art date
Application number
BR9903571-5A
Other languages
English (en)
Inventor
Viriginia Leigh
Dennis Jay Hoover
Markr Ammmirati
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR9903571A publication Critical patent/BR9903571A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)

Abstract

Patente de Invenção: <B>''MéTODO PARA INIBIçãO DE GLICOGêNIO FOSFORILASE HUMANO''<D>. A presente invenção refere-se a um novo sítio de ligação para um inibidor de glicogênio fosforilase encontrado dentro da enzima glicogênio fosforilase. O novo sítio de ligação permite a nova concepção de inibidores de glicogênio fosforilase.
BR9903571-5A 1998-08-07 1999-08-09 Método para inibição de glicogênio fosforilase humano BR9903571A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9579098P 1998-08-07 1998-08-07

Publications (1)

Publication Number Publication Date
BR9903571A true BR9903571A (pt) 2001-03-06

Family

ID=22253599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9903571-5A BR9903571A (pt) 1998-08-07 1999-08-09 Método para inibição de glicogênio fosforilase humano

Country Status (5)

Country Link
US (1) US20020031816A1 (pt)
EP (1) EP0978279A1 (pt)
JP (1) JP2000083662A (pt)
BR (1) BR9903571A (pt)
CA (1) CA2279732A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
EP1741445B1 (en) 2000-01-21 2013-08-14 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CN102050758A (zh) * 2000-09-14 2011-05-11 田边三菱制药株式会社 酰胺衍生物及其制备药物的用途
WO2002070478A1 (en) 2001-03-06 2002-09-12 Astrazeneca Ab Indolone derivatives having vascular-damaging activity
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2005047297A1 (en) 2003-11-12 2005-05-26 Phenomix Corporation Heterocyclic boronic acid compounds
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7786163B2 (en) 2004-07-12 2010-08-31 Forest Laboratories Holdings Limited (BM) Constrained cyano compounds
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
GB0425919D0 (en) * 2004-11-25 2004-12-29 Prosidion Ltd Indole-2-carboxylic acid amides
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EA015735B1 (ru) 2005-09-14 2011-10-31 Такеда Фармасьютикал Компани Лимитед Фармацевтические композиции на основе 2-[[6-[(3r)-3-амино-1-пиперидинил]-3,4-дигидро-3-метил-2,4-диоксо-1(2н)-пиримидинил]метил]бензонитрила
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
CN102834393B (zh) 2010-02-03 2015-07-22 武田药品工业株式会社 细胞凋亡信号调节激酶1抑制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP624A (en) * 1995-06-06 1997-12-19 Pfizer Substituted n-(indole-2-carbonyl)-b- alanimamides and derivatives as antidiabetic agents.
CA2342471C (en) * 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
US20020031816A1 (en) 2002-03-14
JP2000083662A (ja) 2000-03-28
CA2279732A1 (en) 2000-02-07
EP0978279A1 (en) 2000-02-09

Similar Documents

Publication Publication Date Title
BR9903571A (pt) Método para inibição de glicogênio fosforilase humano
BR9809819A (pt) Compostos e métodos para a inibição da expressão de vcam-1
BR9908280A (pt) Inibidores de enzimas de fosfolipase
NO972043D0 (no) Tienopyridin eller tienopyrimidinderivater og deres anvendelse
AU2001248701A1 (en) Inhibitors of histone deacetylase
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
NO996578L (no) Urokinase-inhibitorer
BR9916567A (pt) Combinações de inibidores do transporte ácido dabile ileal e derivados do ácido nicotìnico paraindicações cardiovasculares
MXPA04002397A (es) Inhibidores de histona deacetilasa.
JO2320B1 (en) New pharmaceutical compound
BR9907300A (pt) Inibidores do fator xa oxoaza-heterociclila substituìdos
IL151313A0 (en) Lipase containing pharmaceutical compositions
DK1233958T3 (da) Hæmmere af histondeacetylase
IL165255A0 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer&#39;s disease
WO2000008048A3 (en) Inhibitor of histone deacetylase
AU2002363182A1 (en) Smad7 inhibitors for the treatment of cns diseases
MEP64008A (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
MXPA04003365A (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina.
CY1107776T1 (el) Νεα παραγωγα ολιγο-νουκλεοτιδιων για στοχευμενη αναστολη της εκφρασης γονιδιων
BR9810616A (pt) Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer
EP1093373A4 (en) OLIGONUCLEOTIDES INHIBITORS OF bcl-xL
BR9913526A (pt) Métodos de tratamento da osteoartrite com inibidores de sintase de óxido nìtrico induzìvel
BR0114677A (pt) Inibição da dependência de fator de crescimento de células de tumores
BR0007183A (pt) Isonipectoamidas para o tratamento de distúrbios mediados por integrina
AU2001253601A1 (en) 5-substituted tetralones as inhibitors of ras farnesyl transferase

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A,7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1910 DE 14/08/2007.